Clovis Oncology, Inc. CLVSQ

Market cap: $14.2M
P/E: 0.0×

Follow CLVSQ

Growth Flags show if company had growth for consecutive years

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions

in millions of $

	Nov 25			Feb 26			May 26			Aug 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.22%

Capital & Financial Ratios

Market Cap 14.23

Revenue 133.02

Net Income (251.91)

Free Cash Flow (175.84)

Net Debt 396.79

Current Ratio 0.14

Debt/Equity (1.09)

P/E ratio 0.00

P/S ratio 0.10

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next 5Y EPS Growth —

in millions of $

Dividends

Payout Ratio 0.00

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

	2019	2020	2021	Q'22
Cash	297	240	143	58
Receivables	21	27	27	19
Inventory	27	31	14	11
Other	19	9	12	8
	366	311	198	102

	2019	2020	2021	Q'22
Payables	32	27	27	18
ST’ Debt	5	64	12	438
Other	92	88	9	222
	133	185	125	748

in millions of $

Compound Annual Growth

	10y	5y	3y
Sales	—	352.98%	15.97%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue

	Mar	Jun	Sep	Dec	Year
’26	34	32	31	—	—
’21	38	37	38	36	149
’20	43	40	39	43	165
’19	33	33	38	39	143
’18	19	24	23	30	95
’17	7	15	17	17	56

in millions of $ · fiscal quarters ending in the months shown

Operating Cash Flow

	Mar	Jun	Sep	Dec	Year
’26	(58)	(35)	(41)	—	—
’21	(62)	(47)	(46)	(41)	(196)
’20	(82)	(60)	(54)	(56)	(253)
’19	(98)	(98)	(57)	(70)	(324)
’18	(101)	(110)	(72)	(83)	(366)
’17	(80)	(69)	(46)	(66)	(261)

in millions of $ · fiscal quarters ending in the months shown

Free Cash Flow

	Mar	Jun	Sep	Dec	Year
’26	(59)	(35)	(41)	—	—
’21	(62)	(47)	(46)	(41)	(196)
’20	(83)	(68)	(54)	(56)	(261)
’19	(115)	(99)	(58)	(71)	(342)
’18	(101)	(167)	(398)	236	(430)
’17	(84)	(69)	(46)	(66)	(265)

in millions of $ · fiscal quarters ending in the months shown

EPS

	Mar	Jun	Sep	Dec	Year
’26	(0.44)	(0.50)	(0.39)	—	—
’21	(0.64)	(0.61)	(0.56)	(0.50)	(2.29)
’20	(1.39)	(1.15)	(0.89)	(1.02)	(4.38)
’19	(1.63)	(2.27)	(1.72)	(1.81)	(7.43)
’18	(1.54)	(1.94)	(1.71)	(1.88)	(7.07)
’17	(1.33)	(3.88)	(1.24)	(1.04)	(7.36)

fiscal quarters ending in the months shown

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
—	—	—	—	—	—	—	—	—	—	Analyst estimates 2022–2024 Powerpack	Low Price
—	—	—	—	—	—	—	—	—	—		High Price
—	—	—	—	278	360	468	484	429	413		Employees
—	—	—	—	0	0	0	0	0	0		Revenue/Emp
—	—	—	—	0	56	95	143	165	149		Revenue
—	—	—	—	10.26%	78.86%	76.86%	75.75%	74.89%	73.90%		Gross Margin
—	—	—	—	(381)	(350)	(367)	(399)	(370)	(265)		EBT
—	—	—	—	(488,680.77%)	(630.46%)	(385.16%)	(278.75%)	(224.75%)	(178.09%)		EBT Margin
—	—	—	—	(349)	(346)	(368)	(400)	(369)	(265)		Net Income
—	—	—	—	107	4	8	9	11	11		Depreciation
—	—	—	—	0.00	1.18	1.83	2.65	1.95	1.29		Revenue/Sh
—	—	—	—	(9.07)	(7.36)	(7.07)	(7.43)	(4.38)	(2.29)		Earnings/Sh
—	—	—	—	(6.93)	(5.55)	(7.03)	(6.01)	(3.00)	(1.70)		Cash Flow/Sh
—	—	—	—	(0.02)	(0.09)	(1.23)	(0.35)	(0.10)	0.00		Capex/Sh
—	—	—	—	(6.95)	(5.63)	(8.26)	(6.36)	(3.10)	(1.70)		Free CF/Sh
—	—	—	—	(0.09)	7.81	2.81	(3.23)	(1.88)	(2.41)		Book Value/Sh
—	—	—	—	38	47	52	54	84	116		Shares
—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00		PE Ratio
—	—	—	—	0.00	55.98	9.80	3.93	2.46	2.10		PS Ratio
—	—	—	—	0.00	8.45	6.38	0.00	0.00	0.00		PB Ratio
—	—	—	—	0.00	50.91	10.38	6.65	4.71	5.30		EV/Sales
—	—	—	—	(6.24)	(10.66)	(2.30)	(2.78)	(2.97)	(3.86)		EV/FCF
—	—	—	—	(267)	(261)	(366)	(324)	(253)	(196)		Op' Cash Flow
—	—	—	—	(1)	(4)	(64)	(19)	(8)	0		Capex
—	—	—	—	(267)	(265)	(430)	(342)	(261)	(196)		FCF
—	—	—	—	214	545	447	233	126	73		Working Cap'
—	—	—	—	281	304	577	685	610	619		Total Debt
—	—	—	—	15	(259)	56	388	370	475		Net Debt
—	—	—	—	(4)	368	146	(174)	(159)	(279)		Sh' Equity
—	—	—	—	(64.78%)	(62.99%)	(46.04%)	(52.23%)	(57.91%)	(49.06%)		ROA
—	—	—	—	(2,059.94%)	(137.10%)	(102.86%)	(109.91%)	(89.52%)	(71.85%)		ROIC
—	—	—	—	(235.10%)	(190.33%)	(143.16%)	2,881.99%	221.75%	120.90%		ROE

predictions in italic, sparklines do not include predictions

All 10 years →

Fiscal years to Dec 2021 · latest quarter Sep 2022

Company	Market cap	P/E	Compare
CNSY Cerenome, Inc.	$14.3M	0.0×	Compare
RVLP RVL Pharmaceuticals PLC	$14.1M	0.0×	Compare
TPST Tempest Therapeutics, Inc.	$14.4M	0.0×	Compare
NRSN NeuroSense Therapeutics Ltd.	$14.0M	0.0×	Compare

Company	Market cap	P/E	Compare
HIND Vyome Holdings, Inc.	$14.5M	0.0×	Compare
DARE Dare Bioscience, Inc.	$14.5M	0.0×	Compare
ADAPY Adaptimmune Therapeutics PLC	$14.6M	0.0×	Compare
BIVI BioVie Inc.	$13.8M	0.0×	Compare

All 616 Biotechnology stocks →